Pharma
18 September 2026 The new hire brings more than two decades’ experience managing complex cross-border disputes in life sciences and technology, including most recently at the Unified Patent Court.
17 September 2026
10 September 2026
7 September 2026
3 September 2026
27 August 2026
More News
25 August 2026 While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.
24 August 2026 The four-person team adds significant life sciences experience to the litigation boutique, drawn to move firms by Stris’ “outstanding trial lawyers” and “sophisticated appellate capabilities”.
21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.
20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.
19 August 2026 Questions over braille on a generic sleep disorder drug label will face fresh scrutiny after an appeals court found fault with the FDA’s approach.
17 August 2026 Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.
14 August 2026 Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.
Latest Features
Pharma
A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Pharma
Reflecting on decades of patent searching experience, senior scientist on the CAS IP Services team, David Saari, offers insights into the importance of a multidisciplinary approach in today's competitive IP landscape.
Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Asia
The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox